Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.

导出 OA

翻译打印收藏纠错

第一作者： Dimitrios A,Pappas

第一单位： CorEvitas LLC, Waltham, MA, USA. dpappas@corevitas.com.;Corrona Research Foundation, Albany, NY, USA. dpappas@corevitas.com.

作者： Dimitrios A,Pappas ^[1] ; Jacqueline,O'Brien ^[2] ; Lin,Guo ^[2] ; Ying,Shan ^[2] ; Joshua F,Baker ^[3] ; Gregory,Kricorian ^[4] ; Scott,Stryker ^[4] ; David H,Collier ^[4]

作者单位： CorEvitas LLC, Waltham, MA, USA. dpappas@corevitas.com.;Corrona Research Foundation, Albany, NY, USA. dpappas@corevitas.com. ^[1] CorEvitas LLC, Waltham, MA, USA. ^[2] Department of Rheumatology, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA. ^[3] Amgen Inc., Thousand Oaks, CA, USA. ^[4]

关键词 Adalimumab Biologic/targeted synthetic DMARDs Etanercept Janus kinase inhibitors Patient-reported outcomes

主题词成年人(Adult);人类(Humans);中年人(Middle Aged);关节炎, 类风湿(Arthritis, Rheumatoid);登记(Registries)

DOI 10.1186/s13075-023-03120-9

PMID 37689684

发布时间 2024-10-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交